Intuitive Surgical posted double-digit growth in revenue, procedures, and installed base but ISRG stock is down over 40% from its highs. We dig into why the market is repricing this healthcare stock despite strong fundamentals.

Da Vinci procedure growth came in at 15% year-over-year, the installed base grew 12% to nearly 12,000 systems worldwide, and revenue hit $2.9 billion, up 19% year-over-year. Non-GAAP gross margin expanded to 70%. Yet none of that has stopped the stock's slide.

We break down Intuitive Surgical's revenue mix between recurring instruments and accessories, systems revenue, and services, and walk through what's actually driving the selloff. That includes the impact of ACA subsidy expirations on elective procedure volume, hospital capital spending trends, GLP-1 headwinds on bariatric surgery, and semiconductor memory cost pressures mentioned on the earnings call. We also cover the Extended Use Program and a recent FDA filing as potential positive catalysts, along with full year 2026 guidance.

Finally, we run a reverse DCF to figure out what growth rate is actually priced into ISRG stock today, and whether this sets up as a legitimate buy-the-dip opportunity for long-term investors or if there's more downside ahead.

Semi Insider members get access to CSI's research platform and tools, plus deeper research as it happens. Join at chipstockinvestor.com.

Get 15% off your fiscal.ai membership with our link: fiscal.ai/csi

This content is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted, and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. CSI owns shares of Intuitive Surgical.